Pazopanib Shows Promise in Phase I Pediatric Sarcoma Trial

The multikinase angiogenesis inhibitor pazopanib was well tolerated and exhibited some responses in pediatric patients with soft-tissue sarcomas and other refractory solid tumors in a phase I trial.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: